TY - JOUR
T1 - GATA3 expression in small cell carcinoma of bladder and prostate and its potential role in determining primary tumor origin
AU - Bezerra, Stephania Martins
AU - Lotan, Tamara Levin
AU - Faraj, Sheila Friedrich
AU - Karram, Sarah
AU - Sharma, Rajni
AU - Schoenberg, Mark
AU - Bivalacqua, Trinity J.
AU - Netto, George Jabboure
N1 - Funding Information:
Disclosures: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. This study was partially supported by The Brady Urological Institute–Johns Hopkins Medicine Patana Fund.
Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 2014/8
Y1 - 2014/8
N2 - GATA3 is a sensitive marker for urothelial carcinoma. We here evaluate, for the first time, GATA3 expression in small cell carcinoma of bladder and prostate and assess its utility in the differential diagnosis with small cell carcinoma of lung primary. Archival tissues from 60 small cell carcinomas (12 bladder, 15 lung, and 33 prostate primary cases) were used to build 2 tissue microarrays. We also assessed whole slide sections from 10 additional primary small cell carcinomas of bladder. GATA3 nuclear expression was evaluated using standard immunohistochemistry. Intensity (weak, moderate, and strong) and extent of expression were assessed in each tissue microarray spot. Extent positivity was categorized as focal (1%-25%), multifocal (>25%), and diffuse (>75%). Nuclear GATA3 expression was encountered in 7 bladder (7/22, 32%) and 2 lung (2/15, 13%) small cell carcinomas. All 33 primary prostate small cell carcinomas were negative. Among bladder tumors, strong and diffuse (>75%) GATA3 labeling was seen in 3 cases (3/22, 14%); focal positivity was observed in the 4 remaining cases (4/22, 18%). Both positive lung cases had only focal positivity. Our study is the first to reveal GATA3 expression in the small subset of lung small cell carcinoma that should be taken into consideration in assigning site of origin in advanced small cell carcinoma cases. Our novel finding of GATA3 positivity in one-third of bladder small cell carcinoma is of potential value in differentiating small cell carcinomas of prostate origin from those of bladder origin.
AB - GATA3 is a sensitive marker for urothelial carcinoma. We here evaluate, for the first time, GATA3 expression in small cell carcinoma of bladder and prostate and assess its utility in the differential diagnosis with small cell carcinoma of lung primary. Archival tissues from 60 small cell carcinomas (12 bladder, 15 lung, and 33 prostate primary cases) were used to build 2 tissue microarrays. We also assessed whole slide sections from 10 additional primary small cell carcinomas of bladder. GATA3 nuclear expression was evaluated using standard immunohistochemistry. Intensity (weak, moderate, and strong) and extent of expression were assessed in each tissue microarray spot. Extent positivity was categorized as focal (1%-25%), multifocal (>25%), and diffuse (>75%). Nuclear GATA3 expression was encountered in 7 bladder (7/22, 32%) and 2 lung (2/15, 13%) small cell carcinomas. All 33 primary prostate small cell carcinomas were negative. Among bladder tumors, strong and diffuse (>75%) GATA3 labeling was seen in 3 cases (3/22, 14%); focal positivity was observed in the 4 remaining cases (4/22, 18%). Both positive lung cases had only focal positivity. Our study is the first to reveal GATA3 expression in the small subset of lung small cell carcinoma that should be taken into consideration in assigning site of origin in advanced small cell carcinoma cases. Our novel finding of GATA3 positivity in one-third of bladder small cell carcinoma is of potential value in differentiating small cell carcinomas of prostate origin from those of bladder origin.
KW - Bladder
KW - GATA3 immunohistochemistry
KW - Lung
KW - Prostate
KW - Small cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=84904601707&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904601707&partnerID=8YFLogxK
U2 - 10.1016/j.humpath.2014.04.011
DO - 10.1016/j.humpath.2014.04.011
M3 - Article
C2 - 24925221
AN - SCOPUS:84904601707
SN - 0046-8177
VL - 45
SP - 1682
EP - 1687
JO - Human pathology
JF - Human pathology
IS - 8
ER -